SANUWAVE Health financials
$4.74+1.94%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $9.7M | $9.6M | $13.1M | $11.5M | $10.1M | $9.3M |
| Gross profit | $7.4M | $7.4M | $9.7M | $8.9M | $7.8M | $7.4M |
| Gross margin | 76.2% | 77.3% | 74.1% | 77.9% | 78.1% | 79.0% |
| Operating income | -$280.0K | -$1.1M | $615.0K | $1.5M | $1.4M | $601.0K |
| Net income | -$682.0K | -$1.4M | $6.1M | $10.3M | $551.0K | -$6.1M |
| Net margin | −7.0% | −15.0% | 46.7% | 90.2% | 5.5% | −65.6% |
| Diluted EPS | $-0.08 | $-0.17 | $0.64 | $0.46 | $-0.04 | $-0.72 |
| EBITDA | $33.0K | -$830.0K | $955.0K | $1.7M | $1.6M | $810.0K |
| Operating cash flow | $425.0K | $397.0K | $3.3M | $1.1M | $993.0K | -$1.5M |
| Free cash flow | $91.0K | $374.0K | $3.2M | $556.0K | -$166.0K | -$1.7M |
| Diluted shares | 8.6M | 8.6M | 9.5M | 9.1M | 9.2M | 8.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.4M | $10.8M | $12.0M | $9.6M | $8.5M | $8.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $19.2M | $20.6M | $22.0M | $23.4M | $26.9M | $26.0M |
| Total assets | $36.6M | $37.1M | $37.3M | $35.6M | $33.0M | $30.9M |
| Total liabilities | $33.8M | $35.3M | $35.7M | $38.5M | $47.8M | $48.1M |
| Shareholders' equity | $2.8M | $1.8M | $1.6M | -$2.9M | -$14.8M | -$17.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology